Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

On November 24, 2020 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 (Press release, Eli Lilly, NOV 24, 2020, https://investor.lilly.com/news-releases/news-release-details/lilly-participate-evercore-isi-3rd-annual-healthconx-conference [SID1234571660]). Michael Mason, Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a virtual fireside chat at 2:40 p.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!